and this will conclude on Friday. Next week buyers will rush in scooping up shares of this promising equity and run it up into the $3's.
My fellow Longs know what I am talking about.
Analyst on CNBC from Houston explaining why what fell so quickly will rise quickly, so look for recovery during the third quarter of this year to oil over $70 a barrel.
Cash is King, no bankruptcy talk is possible, reduced staff and lowered cash burn, no more attacks by publicity seeking politicians with ulterior motives, any approval or wise product purchase addition to the pipeline will be big, upward stock price is the direction.
and will soon be in knee deep manure as MHR makes its way into the $4's.
Today institutional managers are selling their dogs and high fliers. Next week in April this stock could attract more buyers looking for opportunities in the energy space, resulting in a run up into the $3's.
I speak Jive and will translate what prophet7721 is trying to convey to MHR Longs. MRH is Code used between Shorts which means: My Rectum Hurts.
GTx Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2015. The GTx presentation will begin at 4:00 pm EDT. Whether the curious timing of the presentation is a coincidence, purposeful or not important, it will be known tomorrow.
kahn_boonie: "I will accumulate more as the price drops"
wazoo_wazoo_wazoo: "You will accumulate more as the price rises".
Maxim Reiterates Buy on AEterna Zentaris Inc. Following 4Q:14 Update
March 19, 2015
by Ben Mahaney,
Editor in Exclusively Published
Maxim Group's healthcare analyst Jason Kolbert came out with a research note on AEterna Zentaris Inc. after the company reported its fourth-quarter financial results and provided a corporate update.
Kolbert noted, "Aeterna announced 4Q results, spending $11M in the quarter and closing the year with $35M in cash, which we add to the $47.2M the company raised (less $5.7M to extinguish outstanding warrants) in 1Q15. With a current net of ~$70M in cash, the company is well positioned to acquire commercial-stage products that fit with its female health focus. We also note that management guided to a reduced burn rate as a result of their restructured R&D effort, prolonging their cash runway."
Furthermore, "AEZS began selling EstroGel, a topical gel for hormone replacement, in December 2014. We expect to see the first launch results in 1Q15. While we believe EstroGel can be a good product we do not see it making a meaningful revenue contribution, instead we believe it helps the company build its commercial focus, setting the stage for additional product acquisitions, which, when combined, can be meaningful, or in other words Estrogel creates strategic value for the company beyond its revenue contribution."
The analyst rates the stock a Buy with a $2.00 price target, which implies an upside of 261% from current levels.
This company stock is a honey of a contrarian in the making and at a sweet accumulation price.
This is Randal J. Kirk's baby and with Intrexon together with other smaller companies and no approval a suitor would only be buying hope.
Sabby Healthcare Master Fund, Ltd.